IBM Faces Securities Probe After $68B Wipeout on Q2 Preannouncement

What happened

IBM shares cratered 25% on July 14, 2026, erasing $68 billion in market value, after CEO Arvind Krishna previewed second-quarter results that fell short of expectations. The plunge has now triggered an investigation by national shareholder rights firm Hagens Berman into potential securities law violations. The underlying results, already detailed in subsequent filings, revealed flat consulting revenue, a 42% collapse in IBM Z mainframe sales, and a broader shift in client budgets toward AI infrastructure that caused large deals to slip. While software segments like Red Hat and Data showed resilience, the overall revenue quality deteriorated, leading management to cut full-year constant-currency growth guidance to 4%–5%. The investigation adds a legal overhang to an already challenging fundamental picture, amplifying the uncertainty around IBM’s ability to convert AI demand into sustainable revenue growth.

Implication

Investors should recognize that the securities probe, while serious, does not alter the underlying operational challenges: IBM’s consulting division is stuck near 1% constant-currency growth, the mainframe cycle is deep in decline, and enterprise budgets are flowing to AI hardware and cybersecurity rather than IBM’s software and services. However, the investigation can still weigh on sentiment, delay institutional participation, and distract management during a critical conversion phase. The stock’s current valuation near our base-case implied value of $230 offers limited upside until IBM demonstrates at least two quarters of improving consulting momentum and sustained software durability. We maintain our WAIT rating but now monitor legal developments as an added risk factor that could widen the discount if the probe uncovers material disclosure issues. A position only becomes compelling if the price falls closer to our $205 attractive-entry level and the fundamental metrics begin to improve.

Thesis delta

The investigation introduces a litigation overhang that could prolong negative sentiment and delay a rerating even if fundamental improvement begins. It does not, however, change our core concern that IBM must show better consulting conversion and software durability to justify a higher multiple. We maintain our WAIT rating while incorporating legal risk as a new monitoring item.